0 Items
Select Page

Puumala Virus

Puumala virus (PUUV) is an emerging Hantavirus that is common in Scandinavia, Western Europe and Russia. PUUV is a rodent borne-disease transmitted by bank voles. In humans, PUUV infection causes nephrophathia epidemica, which is a mild form of haemorrhagic fever with renal syndrome (HFRS) in humans.

Puumala Virus Background

Puumala virus (PUUV) is an enveloped, single-stranded negative-sense RNA virus. PUUV is a Hantavirus that belongs to the Hantavirus genus, within the family Bunyaviridae. Hantaviruses are zoonotic pathogens that have global distribution. Rodents and small mammals act as natural reservoirs for Hantaviruses, with each Hantavirus strain being transmitted by a different rodent host species or related species. Puumala virus is classed as an Arvicolinae-associated phylogroup IV Hantaviruses, and the natural host of PUUV is the bank vole (Kruger, DH).

Airborne transmission of hantaviruses to humans occurs via inhalation of dust or aerosols contaminated by urine, saliva or droppings from infected animals. Cases of hantavirus infection are sporadic and predominantly occur in rural areas where rodents are prevalent. Individuals working with rodents are also potentially at risk of becoming infected with Hantavirus.

In humans, hantaviruses cause two acute febrile disease syndromes, haemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS).  HFRS and HCPS are caused by different strains of hantavirus. The strains of hantavirus causing HFRS are referred to as Old World hantaviruses and include Hantaan, Dobrava, Saaremaa, Seoul and Puumala. Hantavirus strains that cause HFRS are endemic in Europe, Asia and Africa. The clinical symptoms associated with HFRS include fever, renal dysfunction, thrombocytopenia, haemorrhage and shock (CDC). HFRS can be fatal in 1-15% of cases.

Puumala virus is the most common hantavirus in Western Europe, Scandinavia and Russia. It causes a mild form of HFRS known as nephrophathia epidemica. The symptoms of nephrophathia epidemica include fever, muscle pain, thrombocytopenia and myopia. In some cases, acute renal failure may occur, and patients may require dialysis. Diagnosis of PUUV infection is carried out using serological methods. Currently there is no specific antiviral treatment for patients with PUUV infection, or licensed vaccine to prevent PUUV infection.

References

Krüger DH, Schönrich G, Klempa B. (2011). Human pathogenic hantaviruses and prevention of infection. Hum Vaccin. 2011 Jun;7(6):685-93

Centers for Disease Control and Prevention: Hantavirus

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 3 =

Live Customer Feedback

Join our mailing list

* indicates required